Skip to main content
Log in

Correspondence: serum neutralization of SARS-CoV-2 Omicron sublineages BA.1, BA.2 and BA.5 in lung transplant recipients receiving prophylactic tixagevimab/cilgavimab

  • Correspondence
  • Published:
Infection Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Data availability

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

References

  1. Gottlieb J, Simon S, Barton J, et al. Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era. Infection. 2023;51:1481–9.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Vanlerberghe B, Vrij C, Bogaerts K, et al. SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients. J Med Virol. 2023;95:e28736.

    Article  CAS  PubMed  Google Scholar 

  3. Bruel T, Hadjadj J, Maes P, et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022;6:1297.

    Article  Google Scholar 

  4. Touret F, Baronti C, Pastorino B, et al. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5. Sci Rep. 2022;12:12609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. de Lamballerie X, Martin-Blondel G, Dupont A, et al. Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation. J Infect. 2023;86:66–117.

    Article  PubMed  Google Scholar 

  6. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Res. 2020;181: 104880.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank the clinicians of the pneumology ward: Dr. Berengère Coltey, Dr. Nadine Dufeu, Dr. Julien Bermudez, Dr Ana Nieves, and Dr Clarisse Gautier.

Funding

None.

Author information

Authors and Affiliations

Authors

Contributions

Carole Eldin performed statistical analysis of data, interpreted the analysis and wrote the MS. Elif Nurtop, Stephane Priet and Karine Barthelemy performed the technical analysis of samples. Laetitia Ninove supervised the technical analysis of samples. Benjamin Coiffard and Martine Reynaud-Gaubert organized the data collection and the retrospective analysis of patient’s data. Benjamin Coiffard reviewed and corrected the final version of the MS. Nathalie Colombini provided the data about Evusheld and Ronapreve authorization and prescribed doses and corrected the final version of the MS. Xavier de Lamballerie designed the study, supervised the data interpretation, and reviewed and corrected the final version of the MS.

Corresponding author

Correspondence to Carole Eldin.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eldin, C., Nurtop, E., Coiffard, B. et al. Correspondence: serum neutralization of SARS-CoV-2 Omicron sublineages BA.1, BA.2 and BA.5 in lung transplant recipients receiving prophylactic tixagevimab/cilgavimab. Infection (2024). https://doi.org/10.1007/s15010-024-02258-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s15010-024-02258-1

Navigation